Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NTRA 
Natera Inc (NTRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/15/2025: NTRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $197.8
1 Year Target Price $197.8
| 12 | Strong Buy |
| 8 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 37.1% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 22.37B USD | Price to earnings Ratio - | 1Y Target Price 197.8 |
Price to earnings Ratio - | 1Y Target Price 197.8 | ||
Volume (30-day avg) 21 | Beta 1.76 | 52 Weeks Range 110.57 - 183.00 | Updated Date 08/16/2025 |
52 Weeks Range 110.57 - 183.00 | Updated Date 08/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.62 | Actual -0.74 |
Profitability
Profit Margin -12.89% | Operating Margin (TTM) -20.19% |
Management Effectiveness
Return on Assets (TTM) -11.21% | Return on Equity (TTM) -24.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21554325240 | Price to Sales(TTM) 11.39 |
Enterprise Value 21554325240 | Price to Sales(TTM) 11.39 | ||
Enterprise Value to Revenue 10.97 | Enterprise Value to EBITDA -26.8 | Shares Outstanding 137248000 | Shares Floating 132858912 |
Shares Outstanding 137248000 | Shares Floating 132858912 | ||
Percent Insiders 3.21 | Percent Institutions 96.85 |
Upturn AI SWOT
Natera Inc
Company Overview
History and Background
Natera Inc. was founded in 2003. Initially focused on reproductive health, it has expanded its offerings to include oncology and organ health. A key milestone was the launch of Panorama, a non-invasive prenatal test (NIPT).
Core Business Areas
- Reproductive Health: Offers non-invasive prenatal testing (NIPT) services, including Panorama, Vistara, and Horizon, to screen for genetic abnormalities in developing fetuses.
- Oncology: Provides personalized molecular testing, including Signatera, to detect minimal residual disease (MRD) and recurrence monitoring in cancer patients.
- Organ Health: Offers Prospera, a test to assess organ health and rejection risk in transplant recipients.
Leadership and Structure
The CEO is Steve Chapman. The company has a typical corporate structure with departments for research and development, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Panorama: A non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities. Competitors include Illumina (ILMN), Roche (RHHBY).
- Signatera: A personalized ctDNA test used for MRD assessment and recurrence monitoring in cancer. Competitors include Guardant Health (GH), Exact Sciences (EXAS).
- Prospera: A donor-derived cell-free DNA (dd-cfDNA) test used to assess organ transplant rejection risk. Competitors include CareDx (CDNA).
Market Dynamics
Industry Overview
The molecular diagnostics market is growing due to advancements in technology, increasing prevalence of genetic disorders and cancer, and rising demand for personalized medicine.
Positioning
Natera is positioned as a leader in non-invasive genetic testing and personalized molecular diagnostics. Its competitive advantages include its proprietary technology and extensive clinical validation.
Total Addressable Market (TAM)
Estimated TAM is in the tens of billions of dollars across reproductive health, oncology, and organ health. Natera is positioned to capture a significant portion of this TAM with its innovative products and expanding market reach.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Strong clinical validation data
- Established market presence in NIPT
- Expanding product portfolio
- Experienced management team
Weaknesses
- High operating expenses
- History of net losses
- Reliance on reimbursement approvals
- Competition in established markets
- Patent and intellectual property risks
Opportunities
- Expanding into new markets and geographies
- Developing new diagnostic tests
- Partnering with pharmaceutical companies
- Increasing adoption of personalized medicine
- Advancements in genomic sequencing technology
Threats
- Increasing competition
- Changes in reimbursement policies
- Technological disruptions
- Regulatory hurdles
- Economic downturns
Competitors and Market Share
Key Competitors
- ILMN
- GH
- CDNA
- EXAS
- ROCHE.SW
Competitive Landscape
Natera faces competition from established players and emerging companies. Natera's strengths include its proprietary technology and strong clinical validation. Its weaknesses include its high operating expenses and history of net losses.
Major Acquisitions
GeneDx
- Year: 2024
- Acquisition Price (USD millions): 650
- Strategic Rationale: Expand into exome sequencing services and gain access to a large patient database.
Growth Trajectory and Initiatives
Historical Growth: Natera has experienced rapid revenue growth in recent years, driven by increasing adoption of its NIPT and cancer testing products.
Future Projections: Analyst estimates project continued revenue growth for Natera, driven by expansion into new markets and increasing adoption of its products. Profitability is expected to improve over time.
Recent Initiatives: Recent initiatives include expanding its sales force, launching new products, and pursuing strategic partnerships.
Summary
Natera is a growing molecular diagnostics company with innovative technologies in reproductive health, oncology, and organ health. Despite its high operating expenses and history of losses, the company's strong technology and expanding market presence position it for future growth. Reimbursement approvals and competition remain key challenges. Successful execution of strategic initiatives is essential for continued success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, Analyst reports, Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Natera Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2015-07-02 | CEO & Director Mr. Steven Leonard Chapman | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 4424 | Website https://www.natera.com |
Full time employees 4424 | Website https://www.natera.com | ||
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.